Baxalta

HYQVIA

Manufacturer:

Baxalta

Hyqvia HCPCS:

J1575

HCPCS Code Descriptor:

Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

Category:

J Code

Hyqvia NDCs:

00944-2514-02, 00944-2513-02, 00944-2512-02, 00944-2511-02, 00944-2510-02

Primary Type:

Immunoglobulin

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Hyqvia:

HYQVIA is an Immunoglobulin drug manufactured by Baxalta and administered via the Subcutaneous route of administration. The J Code: J1575 is aligned to the drug HYQVIA.

HYQVIA is an immune globulin therapy commonly used to treat primary immunodeficiency. The immune globulin in HYQVIA (J1575) is suspended in recombinant human hyuloranidase, a polysaccharide that temporarily increases the permeability of subcutaneous tissue during treatment. The immune globulin infusion supplies the patient with a wide spectrum of antibodies, protecting them against diseases more effectively. HYQVIA is indicated for use in adults and children over the age of 2.

ACCESS PRICING AND MORE BY REGISTERING

J1575 Added Date:

January 1, 2016

J1575 Effective Date:

January 1, 2016

J1575 Termination Date:

HCPCS Active

Hyqvia billing and coding information can be found through Baxalta at the link below:
Hyqvia patient assistance information can be found through Takeda Patient Support at the URL: https://www.hyqvia.com/patient-support
HYQVIA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for HYQVIA. Please check back in a few weeks.